Campath

Campath) hypotension prolonged immunosuppression (resulting in infectious complications) during treatment. Premedicate with acetaminophen, diphenhydramine, with or without a steroid to alleviate infusion-related reactions. Subcutaneous dosing may lessen acute toxicity. Initially 3 mg/day as a 2-hour infusion, increase to 1 0 mg/day, then 30 mg/day as tolerated. [Pg.1420]

Antibodies Avastin, Bexxar, Erbitux, Herceptin, Humaspect, Humira, Mabcampath/Campath-Hl, Mabthera/ Rituxan, Mylotarg, Neutrospec, Oncoscint, Orthoclone OKT-3, Prostascint, Raptiva, Remicade, Simulect, Synagis, Xolair, Zenapax, Zevalin... [Pg.32]

Mabcampath (EU) or Campath (USA) alemtuzumab a humanized monoclonal antibody directed against CD52 surface antigen of B-lymphocytes) Millennium ILEX (EU) Berlex, ILEX Oncology Millennium Pharmaceuticals (USA) Chronic lymphocytic leukaemia... [Pg.381]

Alemtuzumab (Campath) MoAb to CD52 Third-line B-CLL Phase II... [Pg.447]

The three monoclonal antibodies approved, noted in Table 23.1, in the last 7 years for treatment of patients with cancer include Alemtuzumab (Campath M) (Genzyme Corporation, Cambridge, MA, U.S.A.), Cetuzimab (Erbitux ) (ImClone Corporation, Branchburg, NJ, U.S.A.), and bevacizumab (Avastin ) (Genentech, South San Francisco, CA, U.S.A.). [Pg.449]

Campath was given accelerated approval on the basis of response rate. The pivotal trial was a study in 93 pahents who had been previously treated with an alkylating agent and whose disease had progressed on treatment with fludarabine. The FDA requested a follow-up sfudy for full approval of Campafh by randomizing patients between Campath and chlorambucil (Leukeran) as front-line therapy This trial is ongoing. Thus, Campath has had a convenhonal development approach. [Pg.450]

In summary, these three approvals with the noncytotoxic monoclonal antibodies demonstrated activity based on survival (Avastin), TIP in an enriched population (Avastin in renal cell cancer), a pure response with endpoint (Campath), and a clever response rate to a combination vs. a reference point response rate with that new agent alone (Cetuximab). [Pg.451]

CamPath Alemtuzumab ILEX, Pharmaceuticals Millenium, Cambrige, MA Anti-CD52 Chronic lymphocytic leukemia 2001... [Pg.580]

Alemtuzumab Campath Humanized IgGltc anti-CD52 Chronic lymphocytic leukemia 2001 United States... [Pg.114]

Wing, M.G., Moreau, T., Greenwood, J., Smith, R.M., Hale, G., Isaacs, J., Waldmann, H., Lachman, P.J. and Compston, A. (1996) Mechanism of first-dose cytokine-relaease Syndrome by Campath 1-H Involvement of CD 16 (FCyRlll) and CDlla/CD18 (LFA-1) on... [Pg.465]

Mabcampath (EU) or Campath (USA) Millennium and ILEX Chronic lymphoc5dic... [Pg.417]

B. Indications and nse Campath is indicated for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) in patients who have been treated with alkylating agents and who have failed fludarabine therapy. Determination of the effectiveness of Campath is based on overall response rates. Comparative randomized trials demonstrating increased survival or clinical benefits such as improvement in disease-related symptoms have not yet been conducted. [Pg.299]

Dosage form Campath is a sterile isotonic solution for injection. Each single use ampoule of Campath contains alem-tuzumab 30 mg. [Pg.299]

Recommended dosage and monitoring requirements Campath therapy should be initiated at a dose of 3 mg administered as a 2-hour intravenous infusion daily. When the Campath 3 mg daily dose is tolerated, the daily dose should be escalated to lOmg and continued. When the lOmg dose is tolerated, the maintenance dose of Campath 30mg may be initiated.The maintenance dose of Campath is 30mg/day administered three times per week on alternate days (i.e., Monday, Wednesday, and Friday) for up to 12 weeks. In most patients, escalation to 30 mg can be accomplished in 3 to 7 days. Premedication should be given prior to the hrst dose, at dose escalations, and as clinically indicated. The premedication used in clinical studies was diphenhydramine 50 mg and acetaminophen 650 mg administered 30 minutes prior to Campath infusion. Patients should receive anti-infective prophylaxis to minimize the risks of serious opportunistic infections. [Pg.300]

E. Therapeutic response The safety and efficacy of Campath were evaluated in an open-label study of 93 patients with B-cell chronic lymphocytic leukemia (B-CLL). A partial response was observed in 31% of patients and a complete response in 2%. The median duration of response was 7 months. [Pg.300]

Pharmacokinetics The pharmacokinetic profile of alemtuzumab was studied in a rising-dose trial in non-Hodgkin s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Campath was administered once weekly for a maximum of 12 weeks. Following intravenous infusions over a range of doses, the maximum serum concentration (C ax) and the area under the curve (AUC) showed relative dose pro-... [Pg.300]

CD52 monoclonal antibody, humanized [SY] CAMPATH-1 [TR former reg. to Welcome Foundation]... [Pg.500]

Campath (Mab) B-cell chronic lymphocytic leukemia rCHO... [Pg.136]

Campath CD52 Humanized Chronic lymphocytic leukemia... [Pg.67]

Hale, G., Dyer, M.J.S., Clark, M.R., et al. (1988). Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet, 2, 1394-1399. [Pg.141]

Alemtuzumab [Campath] Chronic lymphocytic leukemia Blood disorders [anemia, leukopenia, neutropenia, thrombocytopenia] chest pain, dyspnea infection nausea... [Pg.578]

See also in sourсe #XX -- [ Pg.506 ]

See also in sourсe #XX -- [ Pg.299 ]

See also in sourсe #XX -- [ Pg.578 ]

See also in sourсe #XX -- [ Pg.3 , Pg.396 , Pg.419 ]

See also in sourсe #XX -- [ Pg.692 ]

See also in sourсe #XX -- [ Pg.5 , Pg.5 , Pg.229 , Pg.233 ]

See also in sourсe #XX -- [ Pg.364 ]

See also in sourсe #XX -- [ Pg.901 ]

See also in sourсe #XX -- [ Pg.352 ]

See also in sourсe #XX -- [ Pg.441 ]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...